Halozyme Therapeutics HALO announced that it has entered into a definitive agreement with Antares Pharma ATRS to acquire the latter for approximately $960 million. The acquisition will add Antares’ ...
Transaction Expected to be Immediately Accretive to Revenue and Non-GAAP Earnings in 2022 with Multiple Drivers to Accelerate Financial Growth Through 2027 and Beyond Augments Drug Delivery Business ...
Halozyme Therapeutics Inc., headquartered in San Diego, and Antares Pharma Inc. of Ewing Township announced April 13 that they entered into a definitive agreement for Halozyme to acquire Antares for ...
EWING, N.J., Aug. 03, 2020 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS), a pharmaceutical technology company, today announced they have entered into an exclusive distribution agreement with ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ:ATRS) today announced that a meeting was held with the U.S. Food and Drug Administration (FDA) to discuss a registration study for the VIBEX ...
Teva Pharmaceutical Industries Ltd and its partner, Antares Pharma, Inc announced the approval of a Supplemental New Drug Application (sNDA), which added 'needle-free injection' to its Tev-Tropin ...
EWING, N.J.--(BUSINESS WIRE)--Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received a Notice of Issuance from the U. S. Patent Office for patent number 8,480,631 entitled “Hazardous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback